NCT02103738 - Canadian Treat and Extend Analysis Trial With Ranibizumab | Biotech Hunter

Enrollment

505

Participants

Timeline

Start Date

May 8, 2013

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions

wetAMD

Interventions

OTHER

0.5 mg Ranibizumab intravitreal injections

All eligible patients will initially be treated in a fixed loading phase, consisting of one intravitreal injection of Ranibizumab 0.5 mg per month for 3 consecutive months (Day 1, Month 1, and Month 2). After the loading phase, patients will be treated according to the treatment arm to which they have been assigned, either a continued once monthly dosing regimen, or an extended schedule of Ranibizumab intravitreal injections as described below. The planned duration of total treatment is 24 months.

Trial Locations (24)

T2H0C8

Novartis Investigative Site, Calgary

T5H 0X5

Novartis Investigative Site, Edmonton

E1C 4B7

Novartis Investigative Site, Moncton

A1A 4A5

Novartis Investigative Site, St. John's

A1B 1S1

Novartis Investigative Site, St. John's

L6Y 0P6

Novartis Investigative Site, Brampton

L8G 5E4

Novartis Investigative Site, Hamilton

N6A 4G5

Novartis Investigative Site, London

L5L 1W8

Novartis Investigative Site, Missisauga

K1H 8L6

Novartis Investigative Site, Ottawa